(S)-2-(6-((2',6'-Dimethyl-4'-(3-(Methylsulfonyl)Propoxy)-[1,1'-Biphenyl]-3-Yl)Methoxy)-2,3-Dihydrobenzofuran-3-Yl)Acetic Acid
| Purity | Grade | Package | Stock | Price | Quantity |
|---|---|---|---|---|---|
| 98% | RG | 100MG | In Stock | 222 USD | |
| 98% | RG | 250MG | In Stock | 434 USD | |
| 98% | RG | 1G | In Stock | 1172 USD | |
Your region is eligible for ordering. Should you have any questions, please contact us by Email. |
|||||
Promotion
Applications of 1000413-72-8
Fasiglifam was primarily developed for managing type 2 diabetes mellitus but was also explored for potential applications in chronic kidney disease due to its effects on glucose metabolism and insulin sensitivity. Despite its promising profile, its clinical development was terminated following reports of liver toxicity during Phase III trials.
NMR spectrum of 1000413-72-8
Safety Information of 1000413-72-8
Download COA of 1000413-72-8
Bulk Packaging Price Explanation of 1000413-72-8
Please email your required order quantity and detailed technical specifications to sales@.
Our sales team will promptly prepare an accurate quotation for your bulk order and provide a comprehensive pricing proposal.
Purchase Instructions of 1000413-72-8
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
